Approved for maintenance treatment of asthma in patients aged 12 years and older
Demonstrated improved lung function compared with inhaled corticosteroid/long-acting beta2-agonist therapy in Phase 3 KALOS and LOGOS trials
Rapid onset of action with lung function improvements within 5 minutes of initial dose
Guideline-Based Recommendations
Diagnosis
Asthma diagnosis based on clinical presentation including symptoms such as wheezing, dyspnea, chest tightness, and exacerbations
Management
Use Breztri (budesonide/glycopyrrolate/formoterol fumarate) as maintenance therapy for asthma patients aged 12 years and older
Not intended for relief of acute bronchospasm or as a substitute for rescue inhalers
Monitoring & Follow-up
Monitor lung function improvements over 12 to 24 weeks
Assess for asthma control and exacerbation frequency
Risks
No new safety or tolerability concerns identified in clinical trials
Patient & Prescribing Data
Approximately 4,300 randomized asthma patients aged 12 years and older, including those with and without recent exacerbations
Improved forced expiratory volume in 1 second and trough lung function compared to dual therapy; rapid onset of action; suitable for maintenance but not acute symptom relief
Clinical Best Practices
Incorporate triple-combination inhaled therapy for patients inadequately controlled on dual maintenance therapy
Continue to use rescue inhalers for acute bronchospasm
Educate patients on the role of maintenance therapy versus rescue treatment
Regularly assess lung function and symptom control to guide therapy adjustments
